SELENBP1 has been shown to be expressed at low levels in cancers such as renal cell carcinoma, lung adenocarcinoma (23), and breast cancer (24) and is generally predictive of poor clinical outcomes. This evidence concerns the gene SELENBP1 and breast cancer.